{Reference Type}: Journal Article
{Title}: Optimizing treatment of mild to moderate ulcerative colitis: CU-forum Delphi consensus.
{Author}: Sans Cuffi M;Argüelles Arias F;Echarri Piudo A;Ginard Vicens D;Gutiérrez Casbas A;Marín-Jiménez I;
{Journal}: Gastroenterol Hepatol
{Volume}: 46
{Issue}: 10
{Year}: Dec 2023 15
{Factor}: 5.867
{DOI}: 10.1016/j.gastrohep.2023.01.014
{Abstract}: <B>OBJECTIVE: </B>Ulcerative colitis (UC) clinical guidelines include the best available evidence, although not all clinical situations are answered, so their management can be controversial. The aim of this study is to identify the situations of mild to moderate UC susceptible to controversy and to evaluate the degree of agreement or disagreement with specific proposals.<BR><B>METHODS: </B>Inflammatory bowel disease (IBD) expert discussion meetings were used to identify criteria, attitudes and opinions regarding the management of UC. A Delphi questionnaire was then developed with 60 items regarding antibiotics, salicylates and probiotics; local, systemic and topical corticosteroids; and immunosuppressants.<BR><B>RESULTS: </B>Consensus was reached in 44 statements (73.3%); 32 in agreement (53.3%) and 12 in disagreement (20.0%). Some of them were: it is not necessary the systematic use of antibiotics despite the severity of the outbreak, being reserved when there is suspicion of infection or systemic toxicity; when faced with a mild-moderate outbreak of UC and in patients who do not respond to aminosalicylates, it is appropriate to use a dose of beclomethasone of 10mg/day for one month and 5mg/day for another month; it is advised that the dose of azathioprine be administered in a single dose.<BR><B>CONCLUSIONS: </B>IBD experts agree on most of the proposals identified for managing mild to moderate UC and there is a need for scientific evidence in some specific situations where expert opinion may be helpful.